November 2023 • PharmaTimes Magazine • 36-37
// YOUR MOVES //
Your Moves
Mover of the Month
Aspire Pharma has announced the appointment of Carolyne Malizia as Chief People Officer. Carolyne has joined Aspire during a period of significant growth for the company and will lead on strategic workforce planning, talent management, organisational development, and HR operations.
Carolyne brings nearly 30 years’ experience in HR with 23 in life sciences, where she has held a variety of roles: notably Global HR Business Partner across Clinical Research, Commercial and Medical, HR operations and Talent Acquisition for a number of organisations.
Carolyne joins Aspire from CSL Seqirus, where she was leading the Global Strategic Talent Planning function, encompassing Strategic Workforce Planning, Early Careers and Succession Management.
Aspire has also announced the appointment of Dr Michael Tzimas to the newly created role of Chief Corporate Development Officer for the Enabling Functions.
Michael’s responsibilities will include Business Development, Portfolio, Legal, International Sales as well as Outcomes Research. He and his team will focus on the international growth of the business.
Michael brings 30 years of pharmaceutical experience, successfully growing business, delivering change, and building teams in the generic and consumer healthcare industries.
Closed Loop Medicine has announced that it has appointed Konstantinos Vlassis as Chief Technology Officer (CTO).
Bringing extensive expertise in designing and implementing technology strategies to support product delivery, Konstantinos will oversee the management of the Company’s technology platforms and will have responsibility for engineering, information security and technology infrastructure.
Konstantinos is an experienced technology leader with more than 20 years of experience in building high performance agile teams. As CTO, he will play a pivotal role in leading Closed Loop Medicine’s Engineering Team and facilitating cross-functional collaboration.
Konstantinos Vlassis, commented: “I am thrilled to be joining Closed Loop Medicine and becoming an integral part of the development of our technology platform and overall software engineering, information security and infrastructure to support bringing these life-changing products to the market.”
Oberoi Consulting has appointed Professor Ahmet Fuat as Medical Director in order to drive forward the company’s range of population health tools and clinical support services to the NHS and pharmaceutical industry.
Prior to joining Oberoi Consulting, Ahmet worked as a GP in the same practice in Darlington for 37 years. He was Darlington PCN CVD and Research Lead, and in 2001 set up the UK’s first one-stop diagnostic clinic for suspected heart failure, then pioneered and ran an integrated heart failure service across primary and secondary care for 20 years.
Ahmet has also held various national roles including President of the new Primary Care Cardiovascular Society.
Ahmet said: “Oberoi’s work not only improves outcomes for patients but also supports an already over-stretched NHS workforce. By working together, we can improve decision-making, enhance accountability and increase productivity in healthcare settings.”
Kavita Oberoi OBE is the founder and managing director of Oberoi Consulting. She added: “The growth of our population health tools and health professional teams is crucial to help stratify patients of highest risk and build capacity in the NHS to improve outcomes for patients."
Fortrea has announced the appointment of Dr John Doyle, as its new President of Consulting. John will serve on Fortrea’s leadership team and lead a team of consultants and advisors with expertise that spans early development through life cycle management.
John will lead Fortrea’s Consulting organisation, which includes drug development, commercialisation and market access advisors with scientific, regulatory and operational expertise spanning several countries.
Its solutions include clinical development and regulatory strategy, real-world evidence, market access, health economics and outcomes research, medical writing and publishing, as well as specialist services, such as paediatric plan development and orphan drug designation.
Current Global has appointed Andrea Hynes-Iatrou as Senior Vice President in its health team, following significant and accelerated growth this year.
The team builds on the success of the last 12 months, adding global product and corporate communications, disease awareness and media relations campaigns for new clients in diverse therapy areas, as well as picking up new assignments with existing clients.
Andrea brings nearly 20 years’ experience in pharmaceutical and consumer health communications.
She has led disease awareness campaigns for the likes of AstraZeneca, BMS and AbbVie, driving conversation and engaging healthcare professionals and patient communities to help improve treatment outcomes.
Veranova has announced the appointment of Dr William Sanders as Global Vice President of Chemical Development Operations.
With over 25 years in the chemical and pharmaceutical industries, William brings a wealth of experience to Veranova across multiple pharmaceutical modalities.
William most recently served as Senior Director, Research and Development at Actylis. At Actylis, his collaboration with the business development team contributed significantly to the provision of essential technical support to clients and prospects.
Prior to Actylis, he dedicated 16 years of expertise to MilliporeSigma/SAFC, where he gained significant experience with highly potent APIs, including vitamin D analogues, sex hormones and various small-molecule oncology drugs.
Publicis Groupe UK has named Victoria Wright as the new CEO of Publicis Health UK. She takes over from Philip Chin, who is stepping down after 40 years in the industry.
Victoria takes up the role following more than 13 years with Publicis Groupe, most recently in the post of CEO of Langland.
In this role, she united the specialisms of clinical trial experience, medical strategy and education, public relations and advertising under one P&L to offer healthcare clients a single proposition. She was previously group managing director, after being promoted from managing director in 2019. Before this, she was general manager of Publicis Resolute, an agency she joined in 2007.
She will work closely with the other members of the Publicis Health UK leadership team to leverage the full power of its capabilities, expand its reach to existing and new clients and continue to attract and retain the best talent in the industry.
Victoria said: “The health industry is in an intense period of change, change that presents new challenges and opportunities for our stakeholders. I am looking forward to leading Publicis Health into its next chapter.
“I firmly believe we will create something new and powerful together that clearly sets us apart from the rest of the pack, and ultimately make a real difference to patients’ lives through the work we do for our clients.”
The British In Vitro Diagnostic Association (BIVDA) has announced the appointment of Helen Dent as Interim Chief Executive Officer.
Helen will replace outgoing CEO, Doris-Ann Williams, who has retired from her role. Helen will lead the organisation in championing the in vitro diagnostics (IVD) industry to politicians, policymakers, media and relevant stakeholders, and in supporting members to improve patient outcomes.
Helen, who will step into the role following over three years as Chief Operating Officer at BIVDA, brings over twenty years of industry experience to the business. Prior to her role at BIVDA, she occupied the roles of Supply Chain and Contracts and Pricing Manager for Abbott Diagnostics in the UK and Europe.
Helen said: “I want to ensure that their voices are heard, amplified and considered and that the value of IVD testing is understood, ultimately to improve patient outcomes, by increasing adoption of IVDs within the NHS.”
Spexis has announced that the company has appointed Gonçalo Bernardes, as acting Head of Chemical Biology.
Gonçalo is a leader in the fields of chemistry and oncology and currently a Full Professor at the University of Cambridge. He also leads a satellite lab at the Insituto Medicina Molecular in Lisbon. Multiple discoveries made in his lab have been translated into leading biopharmaceutical companies.
“We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, Chairman & CEO of Spexis.
“Dr Bernardes will be instrumental in driving value out of our macrocycle platform to produce novel therapeutics for the treatment of cancer and rare diseases. In the coming weeks and months, we will reveal what some of these initiatives are, which are already underway,” he added.
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.